Concepedia

Cost-Effectiveness of LDL-C Lowering With Evolocumab In Patients With High Cardiovascular Risk In The United States

SR Gandra, G Villa, Gregg C. Fonarow, Mickael Löthgren, Peter Lindgren, Ransi Somaratne, B. van Hout

Value in Health · 2016 · 62 citations · 2 references

Concepts

PharmacyInternal MedicinePharmacoeconomicsClinical PharmacologyCost-effectiveness AnalysisCost-utility AnalysisCardiovascular DiseaseCardiovascular Risk ReductionCost-effectiveness ComparisonDyslipidemia ManagementDyslipidemia PharmacotherapyLipid-lowering TherapyAtherosclerotic Cardiovascular Risk ReductionCardiovascular Risk MarkersLdl Cholesterol LoweringLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol Reduction

References

2

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott · Journal of Vascular Surgery · 2015 · 361 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Guidelines - Familial hypercholesterolaemia: summary of NICE guidance

Anthony S. Wierzbicki, Steve E. Humphries, Rubin Minhas et al. · UCL Discovery (University College London) · 2008 · 20 citations

Medicine, Cardiology, Internal Medicine +14